The company’s revenue from operations increased 12.5% to ₹149 crore as against ₹132 crore in the corresponding period of the preceding fiscal.
At the operating level, EBITDA was flat at ₹24.5 crore in the first quarter of this fiscal. EBITDA margin stood at 16.5% in the reporting quarter as compared to 18.5% in the corresponding period in the previous fiscal.
Also Read: Bajaj Healthcare Q3 Results: Swings to profit, revenue jumps 13% on-year
Anil Jain, Managing Director, said, “Q1 FY26 marks a strong and promising start to the new fiscal year for Bajaj Healthcare, despite a challenging pricing environment in certain segments. Revenue from operations rose 12.5% year-on-year to ₹148.84 crore, while PAT grew by 66% to ₹11.83 crore, reflecting improved profitability and sharper execution across business segments.
EBITDA remained steady at ₹25.39 crore, with margins improving sequentially to 17.0% from 15.1%, reflecting better product mix and improved operating leverage, even amidst input cost pressures.
Segment-wise, our API export business delivered standout growth of 68.4% YoY, supported by growing demand in regulated markets and the ramp-up of commercial CDMO supplies. Formulations saw 41.1% year-on-year growth, led by deeper market penetration and new strategic partnerships.
Also Read: Bajaj Healthcare Q4 results: Swings to profit, revenues up 15.4%
Due to pricing headwinds in the domestic API segment, the company has strategically realigned its portfolio towards value-added exports and differentiated molecules to reinforce growth and profitability.”
The results came after the close of the market hours. Shares of Bajaj Healthcare Ltd ended at ₹527.75, up by ₹10.90 or 2.11% on the BSE.
